SAN FRANCISCO -- Two mainstream devices for percutaneous left atrial appendage (LAA) closure continued to lead to similar clinical outcomes in the SWISS-APERO trial. Among patients randomized to the ...

DEAR DR. ROACH: I am a 70-year old woman with a prior history of asymptomatic atrial fibrillation (AFib). I’ve been in normal sinus rhythm since having two catheter ablations in 2018. I take Eliquis ...

Any leakage around a percutaneous left atrial appendage (LAA) implant, no matter how small, predicted strokes and other thrombotic events after the procedure, according to a retrospective study. In ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Boston Scientific’s CHAMPION-AF trial found the Watchman FLX left atrial appendage closure device to be statistically superior to leading blood thinners in reducing major bleeding, while matching them ...

Boston Scientific (NYSE:BSX) released new clinical trial results for its FARAPULSE PFA Platform and WATCHMAN LAAC at Heart ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: I am a 70-year old woman with a prior history of ...

ROCHESTER, MN – The PREVAIL study, a clinical trial evaluating the safety of the Watchman (Boston Scientific) left atrial appendage (LAA) closure device in the treatment of patients with nonvalvular ...

Columbus Regional Health Heart & Vascular announced that its cardiovascular services team recently completed its 100th Watchman™ procedure, which treats patients with atrial fibrillation (AFib).

Boston Scientific's Watchman device performed well in the recent quarter, but analysts are focused on upcoming reimbursement decisions for the device and the potential impact on Watchman adoption ...